Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Analysis
  • Published:

Pioneering apoptosis-targeted cancer drug poised for FDA approval

Nature Reviews Drug Discovery volume 15, pages 147–149 (2016)Cite this article

Subjects

An Erratum to this article was published on 11 March 2016

This article has been updated

AbbVie's BCL-2 inhibitor venetoclax — the leading small-molecule protein–protein interaction inhibitor — could soon become the first marketed drug to directly target the ability of cancer cells to evade apoptosis.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 11 March 2016

    Nature Reviews Drug Discovery 15, 47–149 (2016). Martin Dyer's affiliation was incorrect. He is at the University of Leicester, UK. This has been corrected in the online version of the article.

Authors
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mullard, A. Pioneering apoptosis-targeted cancer drug poised for FDA approval. Nat Rev Drug Discov 15, 147–149 (2016). https://doi.org/10.1038/nrd.2016.23

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2016.23

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research